Kael GemVax malaria vaccine wins European patent

Kael GemVax won a European patent for its malaria vaccine and will be notified by the European Patent Office on June 4.

The patented technology is for the production of a vaccine that could prevent or treat malaria caused by plasmodium falciparum. According to the World Health Organization, malaria affects 500 million people around the world and kills 1 million every year.

The technology gained a U.S. patent in September 2011. “We hope the patent will provide a platform for scientists to develop DNA vaccines in the future,” a spokesman of the drugmaker said.

(baejisook@heraldcorp.com)